Development
Ekso Bionics Holdings, Inc.
EKSO
$3.14
-$0.11-3.39%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 4.49% | 20.45% | 3.62% | -38.11% | 26.16% |
| Total Depreciation and Amortization | 97.37% | 28.09% | -35.51% | 60.47% | 54.49% |
| Total Amortization of Deferred Charges | -396.34% | -49.07% | -- | -- | -400.00% |
| Total Other Non-Cash Items | -68.72% | 78.04% | 55.96% | 190.33% | -130.24% |
| Change in Net Operating Assets | 169.24% | -439.33% | 168.73% | -57.66% | -202.87% |
| Cash from Operations | 52.76% | -15.50% | 31.11% | -15.64% | -40.69% |
| Capital Expenditure | -152.94% | 69.09% | -30.95% | 20.75% | 62.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -152.94% | 69.09% | -30.95% | 99.17% | -3,470.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | 100.00% | -250.00% | -65.22% | 2,400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.45% | -13.47% | 30.08% | 50.92% | -216.80% |